` RDG (Read Gene SA) vs WIG20 Comparison - Alpha Spread

R
RDG
vs
W
WIG20

Over the past 12 months, RDG has underperformed WIG20, delivering a return of +30% compared to the WIG20's +33% growth.

Stocks Performance
RDG vs WIG20

Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
RDG vs WIG20

Loading
RDG
WIG20
Difference
www.alphaspread.com

Performance By Year
RDG vs WIG20

Loading
RDG
WIG20
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Read Gene SA vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Read Gene SA
Glance View

Market Cap
71.2m PLN
Industry
Biotechnology

Read-Gene SA engages in the medical research and testing. The company is headquartered in Szczecin, Woj. Zachodniopomorskie. The company went IPO on 2009-02-12. The company is focused on technologies which aim is to detect, prevent and treat malignant tumors. The firm specializes in three fields: chemoprevention, clinical trials and genetic testing. The company offers breast cancer, colon cancer and prostate cancer tests, as well as, medical consultancy, DNA tests and supplements. The firm operates one wholly owned subsidiary, Dieta Antyrakowa Read-Gene Sp. z o.o. Its major shareholder is GEN-PAT-MED Sp. z o.o.

RDG Intrinsic Value
2.39 PLN
Overvaluation 60%
Intrinsic Value
Price
R
Back to Top